Affordability of essential medicines used for treating chronic diseases in Malaysia: An academic perspective
|
|
- Raymond Dalton
- 6 years ago
- Views:
Transcription
1 ISPUB.COM The Internet Journal of Third World Medicine Volume 8 Number 1 Affordability of essential medicines used for treating chronic diseases in Malaysia: An academic H Ahmed, M Ibrahim, Z Babar Citation H Ahmed, M Ibrahim, Z Babar. Affordability of essential medicines used for treating chronic diseases in Malaysia: An academic. The Internet Journal of Third World Medicine Volume 8 Number 1. Abstract The aim of this study is to measure the affordability of drugs used in treating common chronic diseases. The study was conducted in the Universiti Sains Malaysia (USM) and in 5 private retail pharmacies. The study measured prescriptions contents of Universiti Sains Malaysia panel of clinics claim forms of patients for the year Affordability of medicines used was calculated using private retail pharmacies prices. Affordability was expressed as the number of days salary required by lowest wage earners to pay for one month treatment. The number of day s salary would have to pay by the worker ranged from days, days, days and days wage for the treatment of hypertension, diabetes, asthma and for multiple conditions, respectively. Low affordability was noted for most of the branded products, most combined treatments and all multiple chronic cases treatments. Government must intervene to ensure affordability of medicines among the public. IMPACT OF FINDINGS ON PRACTICE Prescribers should be encouraged to prescribe generic medicines if proven cost-effective based on evidence Government should set up Good Prescribing & Dispensing Practices policy to ensure medicines prescribed and dispensed are rational, accessible and affordable to the general public INTRODUCTION Affordable medicine prices are an important prerequisite for ensuring access to essential drugs in the public and private sectors. The issue is to ensure access to essential drugs (ED) through appropriate prices (i.e. affordable drugs), as affordability is defined as free access to goods and services [1] and moreover, high drugs prices lead to barrier towards affordability [2]. Affordability prices are an important prerequisite for ensuring access to essential medicines, both in the public and private sectors. It is one of the specific objectives of the National Medicines Policy which emphasis on access to equitable availability and affordability of essential medicines to those who need them. Great benefits have been gained through the use of an essential drugs list in the public sector. However, in most low- and middle-income countries the majority of people are treated with drugs bought from the private sector. These consumers often purchased high-priced drugs, in small quantities, rather than in therapeutic amounts of essential drugs. The widespread prescription and sale of non-essential drugs means that households, especially poor households, are not getting the best health care value for their money and may ultimately not receive the treatment needed [3]. Therefore, in many countries even the developed nations, have applied the essential drugs list in order to improve care and manage drugs costs as the list serves to maintain drug affordability amongst a selection of essential drugs [4]. In fact, access to health care, which includes access to ED, is a prerequisite for realizing the human right i.e. the right to health [5]. The causes of access gap to essential drugs and the measures which are needed to close the gap is linked to a set of fundamental economic, social and educational factors that lie beyond the health sector system [6]. However, it should be noted that access to essential medicines helps to reduce disease burden [2]. Affordability also refers to the cost of treatment in relation to people s income [7]. High costs of medicines results in poor access to the public, even in rich countries [8]. Moreover, the WHO has reported that many people throughout the 1 of 8
2 world cannot obtain the drugs they need due to its unaffordability. [3] Due to fact that Malaysia as a developing nation has no regulatory system for drug pricing [9], imported drugs prices have increased by up to 28 per cent annually over the last 10 years, especially for medicines used daily [10]. Most medicines prices ranged from % higher than in Australia and UK. Furthermore, such price increases up to 20.7% per annum vis-à-vis a rate of inflation was 7% [11]. A survey on the median prices ratios for some essential drugs for innovator brand (IB) showed that it was 16 times higher than the international reference prices [12]. The most sold generic (MSG) and the lowest priced generic (LPG) in the private retail pharmacy were 6.89 and 6.57 times higher than the international prices, respectively. Basically chronic diseases need treatment over a life time, and if a patient cannot afford medicines this may lead to more serious illnesses and complications. For instance, drugs for the treatment of pneumonia are hardly affordable in Malaysia [13]. In addition, treatments cost of some disorders such like hypertension, asthma and respiratory disorder are expensive due to costly branded and generic medicines [12]. Therefore, there is a need to study actual prescriptions prescribed by physicians in a government organization to its employee. This study aims to measure affordability of drugs used in treating hypertensive, diabetic and asthmatic patients, and patients with multiple diseases (i.e. combination of any of these diseases). MATERIALS & METHODS The case study method was used to assess drugs affordability in Malaysia, with the Universiti Sains Malaysia (USM) (which is a government institution) employee being used as an example to evaluate affordability of prescriptions based on diseases. A retrospective study design was used to measure medicines affordability of different treatment regimens for diabetes type II, hypertension, asthma and multiple cases of diseases. This study sourced its data from USM panel clinics claim forms for the year The university community (staff, student, pensioner and dependant) can obtained their prescriptions either from the university clinic or panel of private clinics and pharmacies. The panels have signed an agreement with the university to provide services to the university community. An individual can have an option to receive their medication from the 2 of 8 clinic or pharmacy. Due to the difficulty to obtain prices of medicines from the private clinics, prices of medicines from the pharmacies were studied. Affordability of medicines was expressed as the ratio of prescription cost in private retail pharmacies to the lowest paid USM worker wage. A non-intervention, descriptive cross-sectional survey was used to measure the prices of drugs obtained from the private retail pharmacy. This method was adopted from WHO/HAI methodology for measuring drugs affordability. It took into consideration the actual cases and prescriptions by measuring affordability of prescriptions of staff in the university, unlike the WHO/HAI method which depended on hypothetical diseases conditions [14]. Disease selection was made based on the prevalence of diseases in the university. The sample was chosen according to the findings of a survey which found that hypertension, diabetes and asthma constituted 50% of all prevalent diseases in Malaysia [15]. Procedure for selection is for those diseases which their treatments are for a life time. A drugs check list was prepared using the Malaysian national essential drug list [16] in order to identify drugs used for the treatment of diabetes type II, hypertension and asthma. Both core and supplementary drugs (i.e. essential medicines) from the national list were included. The USM panel clinics claim forms used in this evaluation were for the year One inclusion criteria for this study was that all claim forms must be for the university staff who were diagnosed with diabetes type II, hypertension, asthma and any possible multiple conditions. Five private retail pharmacies within 5 kilometres radius from the university campus were selected. A data collection form was developed to investigate the content of each claim form, including the details about the medicines prescribed. The Microsoft Office Excel software was used to analyse the data. Median drugs prices and median cost of each prescription were calculated. The number of days salary a USM worker spend to pay for each prescription was calculated to express the affordability for a treatment period of one month. This method is adopted from the WHO/HAI methodology. A treatment cost exceeding one day wage was considered as not affordable [14]. Figure 1 shows the flow of the study.
3 Figure 1 Figure 1: Study flow chart one day salary. Prescriptions costs ranged from days salary. The affordability of prescriptions depended on the choice of therapeutic class, amount of drugs prescribed, and whether the drugs were generic or brand. (Table 1) Figure 2 Table 1 Number of days salary required to pay for a month hypertension treatment by the lowest unskilled USM worker AFFORDABILITY OF DRUGS USED IN TREATING DIABETES TYPE II PATIENTS AFFORDABILITY OF PRESCRIPTIONS CONTAINING ONE MEDICINE The majority of drugs used in treatment of diabetes type II were affordable even for the IB products of some drugs. However, some IB drugs cost more than a day s salary. Prescriptions costs ranged from days salary. (Table 2) Figure 3 Table 2 Number of days salary required to pay for a month diabetes type II treatment by the lowest unskilled USM worker AFFORDABILITY OF PRESCRIPTIONS CONTAINING TWO MEDICINES RESULTS The median for unit prices of drugs mentioned in the claim forms were obtained from the survey on five private retail pharmacies. AFFORDABILITY OF DRUGS USED IN TREATING HYPERTENSIVE PATIENTS The majority of drugs used in treatment of hypertension were affordable, except some IB drugs which cost more than 3 of 8 The majority of prescriptions containing two drugs used in treatment of diabetes type II were not affordable even when both drugs are generic products. Prescriptions costs ranged from days salary. (Table 3)
4 Figure 4 Figure 6 Table 3 Median diabetes type II prescriptions costs and number of days salary required to pay for a month treatment by the lowest unskilled USM worker. Table 5 Median asthma prescriptions costs and number of days salary required to pay for a month treatment by the lowest unskilled USM worker. AFFORDABILITY OF DRUGS USED IN TREATING ASTHMATIC PATIENTS AFFORDABILITY OF DRUGS USED IN THE TREATMENT OF PATIENTS WITH MULTIPLE CONDITIONS AFFORDABILITY OF PRESCRIPTIONS CONTAINING ONE MEDICINE The majority of drugs used in the treatment of asthma were affordable even for IB product of some drugs, except few IB drugs which cost more than a day s salary. Prescriptions costs ranged from days salary. (Table 4) Figure 5 Table 4 Median asthma prescriptions costs and number of days salary required to pay for a month s treatment by the lowest unskilled USM worker. All prescriptions containing two drugs used in the treatment of multiple cases were not affordable, even when both drugs are generic products. Prescriptions costs ranged from days salary. (Table 6) Figure 7 Table 6 Median diabetes type II prescriptions costs and number of days salary required to pay for a month treatment by the lowest unskilled USM worker DISCUSSION AFFORDABILITY OF PRESCRIPTIONS CONTAINING TWO MEDICINES All prescriptions containing two drugs used in the treatment of asthma were not affordable even for generic products of both drugs. Prescriptions costs ranged from days salary. (Table 5) 4 of 8 Unaffordable of medicines especially for chronic diseases is a critical issue particularly for the bottom billion. This refers to majority of the world population which populated in the developing nations. Economic consequences of not making chronic care maintenance medications available at affordable prices can be severe. It is because if that is not done, the country will have an economic disaster sometime
5 in the future with unnecessary amputations, heart attacks, kidney failures, strokes from uncontrolled diabetes, hypertension, etc. This will affect not just the quality of life of the person and family, but also the productivity of the country. This study has looked into cases, single disease and multiple diseases. This study actually has contributed a significant part where it has considered the actual prescriptions and medicines prescribed to patients, compared to WHO/HAI study protocol which looked at hypothetical cases and not the actual prescriptions. HYPERTENSION TREATMENTS In Malaysia, the prevalence of hypertension is high [17]. Treatment of hypertension is important because if patients ignore drug administration due to unaffordable reason, serious complications may occur. Affordability of innovator brand is less than generic and this may be due to the fact that IB products were higher priced than generic ones. IB amlodipine 5 mg tablet had the lowest affordability among hypertensive drugs as well as other conditions, because it is still under patent and no generic alternative were available. This finding complied with the results of a study done in Malaysia in 2007 by Babar et al., [12] who found that a worker would have to spend 4 days salary to buy IB amlodipine from a private retail pharmacy. Another report stated that IB amlodipine 5 mg tablet once per day was also unaffordable in China as it cost 14.3 days salary [18]. Another finding found that IB amlodipine 5 mg tablet once per day cost the patient 8.1 days salary [19]. The high cost of IB amlodipine 5 mg tablet may be due to fact that it is still under patent and no generic product is available. In Malaysia, the treatment of hypertension using atenolol 50 mg is much more affordable than in Kenya [20]. The cost was also lower than in Mongolia where it amounted to 1.1 days salary [7]. DIABETES TYPE II TREATMENTS The treatment of diabetes type II using one drug is affordable even for some IB products, but the situation is different with prescriptions containing more than one drug. This finding is similar to the cost of glibenclamide 5 mg tablet twice a day which cost 1.0 days salary in Mongolia [7]. In contrast IB drugs cost 6.1 days salary and 3.9 days salary using the most sold generic in Nigeria [20]. The finding of this study is in line with the study of affordability of medicines in Uganda where the treatment of patients with 5 of 8 glibenclamide two tablets per day exceeded one day s salary, while it exceeded two day s salary in Peru [21]. However, no data was available to compare affordability of gliclazide 80 mg with that in other countries. In general, innovator brand and generic metformin 500 mg tablet is affordable for USM employees and this result differed with that in Mongolia, where the cheapest generic metformin 0.5 g tablet administer twice a day cost the patient 1.0 days salary [7] while in Shanghai province of China, it costs 3.6 days salary [19] and 10.8 days salary in Shandong province, China [18]. ASTHMA TREATMENTS The majority of asthma treatment involving the use of one drug was affordable for the exception being the use of the innovator brand, salbutamol 4 mg tablets three times per day and the innovator brand ketotifen 1 mg tablet twice per day. The case was different when patients used two medicines, as in such cases treatment were not affordable at all. MULTIPLE CASE CONDITION TREATMENTS The treatment of hypertension and diabetes type II using two different prescription regimens were not affordable even if generic products were used. This is mainly due to the fact that diabetes is a condition of many co-morbid conditions, and its incidence and prevalence is very difficult to quantify as persons are often present with cardiovascular complications [22]. STUDY LIMITATIONS AND RECOMMENDATIONS This study was conducted with few limitations. Firstly, the method to measure affordability is based only on the study methodology provided by WHO/HAI. This is the only reliable and validated method available. Even the definition of what is affordability and not affordable is based on consensus provided by them and open to criticism. Secondly, the study did not consider all possible treatments suffered by all family members; it was only for one person (i.e. staff). The situation will be worse (i.e. unaffordable) if a family has a single income earner with more than one person experiencing chronic diseases. Thirdly, due to the difficulty to obtain prices of medicines from the private clinics, only prices of medicines from the pharmacies were studied. The authors are not certain of the cost of prescription in the clinics whether it is more expensive or less expensive compared to the pharmacies. It is recommended for future study to look into the price of medicines and cost of prescriptions in the private clinics due
6 to the fact that Malaysia has dispensing doctors. Furthermore, future study is also encouraged to look into affordability of medicines in a family. It is also accepted the notion that the reason for price rises in Malaysia probably go well beyond absence of a price regulatory system. It is one of the reasons and government is encouraged to take appropriate action, while study can be carried out to look into other possible reasons for price hike. CONCLUSION It can be concluded that most of the medicines surveyed were not affordable. Affordability is largely dependent on the choice of therapeutic class and the product itself. It also depends on diagnosis whether it is a single disease or multiple diseases, the number of medicine per prescription, and whether drugs prescribed are brand or generic. In general, medicines which are unaffordable to a low paid worker will be much less affordable for a significant proportion of the population who have an income less or equal to that worker. Patients with chronic diseases, such as hypertension, diabetes and asthma, require affordable medicines due to the fact that their medication is for a life time. ACKNOWLEDGEMENT The authors would like to thank the management of Universiti Sains Malaysia who has approved the request to conduct this study in the campus. Further acknowledgement to Norlela Maarup, MD for her clinical information provided in this study. References 1. Lee J. A. & McKercher P. L. Statistical comparison of consumer drug expenditures and discretionary purchases to assess drug affordability. Clinical Therapeutics. 2002;24 2. Tetteh EK. Provide Affordable essential medicines to African households: The missing policies and institutions for price containment.. Soc Sci & Med : World Health Organization. How to develop and implement a national drug policy. 2nd ed. Geneva: WHO; 2001a. 4. Reidenberg MM, Walley, T. The pros and cons of essential medicines for rich countries. BMJ. 2004;329, Hogerzeil HV. Boosting access to essential medicines for children. The Lancet. 2006;368, Quick JD. Essential medicines twenty-five years on: closing the access gap. Health Policy and Planning. 2003;18, Munkhdelger C. Survey of medicine prices, availability, affordability and price components in Mongolia. [Online]. [Accessed 24th August 2006]. Available from World Wide Web: sdocs/mongoliareportfinal.pdf. Ulaanbaatar; Lopert R, Lang, D. L., Hill, S. R. & Henry, D. A. 6 of 8 Differential pricing of drugs: a role for cost-effectiveness analysis? Lancet. 2002; Ibrahim MIM, Bahri, S. Drug Policies and Pricing Mechanism: The Malaysian Perspective. In: Wertheimer AI, Smith, M. C. editor. International Drugs Regulatory Mechanisms. New York: Pharmaceutical Products Press; p. pp Azhar S. (2006) Prices of Drugs Used Daily Rising Steadily [Online]. [Accessed 24th August 2006]. Available from World Wide Web: &sec=. The Star online Chowdhury Z. The Politics of Essential Drugs The Makings of a Successful Health Strategy Lessons from Bangladesh.. London: Zed Books Ltd; ISBN X Cased 12. Babar ZU, Ibrahim, M. I., Singh, H., Bukahri, N. I., Creese, A. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med. 2007;4:e Saleh K, Ibrahim, M. I. M. Are essential medicines in Malaysia accessible, affordable and available. Pharmacy World & Sciences. 2005;27: Gelder S, Ewen, M., Noguchi, N., Laing, R.. Price, availability and affordability An international comparison of chronic disease medicines. Cairo: World Health Organization Regional Office for the Eastern Mediterian and Health Action International Document Number WHO-EM/EDB/068/E/05.06/ Ministry of Health (2006) National Drugs List [Online]. [Accessed 22th June 2006]. Available from [updated 2006; cited]. 16. Babar ZU, Ibrahim, M. I. M., Bukhari, N. I. Medicine utilisation and pricing in Malaysia: The findings of a household survey. Journal of Generic Medicines. 2005;3: Rampal L, Rampal, S., Azhar, M. Z. & Rahman, A. R. Prevalence, awareness, treatment and control of hypertension in Malaysia: A national study of 16,440 subjects. Public Health. 2008;122: Qiang S. Survey of Medicine Prices, Availability, Affordability and Prices Components in Shandong Province, China. [Online]. [Accessed 24th October 2006]. Available from World Wide Web: urvey_report.pdf. Shandong; Ye L. Survey of Medicine Prices, Availability and Affordability in Shanghai, China using the WHO/HAI Methodology, Shanghai.[Online]. [Accessed 24th May 2007]. Available from World Wide Web: survey_report.pdf; World Health Organization Medicine Prices in Nigeria Prices People Pay for Medicines. [Online]. [Accessed 8th December 2006]. Available from World Wide Web: urvey_report.pdf. Kano and Lagos: Federal Ministry of Health, WHO, DFID, EU and HAI; Ewen M, Dey, D.. Medicines: Too Costly and Too Scarce [Online]. [Accessed 8th December 2006]. Available from World Wide Web: [updated 2005; cited]; Available from: paperfinal.doc 22. Kunath KS, Geadelmann, J. M., Riggs, S., Appelgate, W. K. Chronic Diseases A critical Issue for Iowa. [Online].
7 [Accessed 20th April 2008] Available from World Wide Web: 7 of 8 c_diseases.pdf. Lowa; 2005
8 Author Information Hind Mahjowb Abdallah Ahmed, MSc Candidate Social & Administrative Pharmacy School of Pharmaceutical Sciences Universiti Sains Malaysia Penang, Malaysia Mohamed Izham Mohamed Ibrahim, PhD Deputy Dean of Research & Postgraduate Study, Social & Administrative Pharmacy School of Pharmaceutical Sciences Universiti Sains Malaysia Penang, Malaysia Zaheer-Ud-Din Babar, PhD Lecturer in Pharmacy Practice, School of Pharmacy Faculty of Medical & Health Sciences The University of Auckland 85 Park Road, Grafton New Zealand 8 of 8
Tunisia. Medicine prices, availability, affordability and price components. Medicine prices matter. Tunisia
prices, availability, affordability and price components prices matter Rapidly rising costs of health care and high medicine prices are a growing concern worldwide, especially in developing and transitional
More informationShanghai. China. Medicine prices, availability and affordability
Shanghai China Medicine prices, availability and affordability Medicine prices matter Rapidly rising costs of health care and high medicine prices are a growing concern worldwide, especially in developing
More informationIslamic Republic of Iran
Islamic Republic of Iran prices, availability, affordability and price components prices matter Rapidly rising costs of health care and high medicine prices are a growing concern worldwide, especially
More informationKyrgyzstan. Medicine prices, availability, affordability & price components
Kyrgyzstan Medicine prices, availability, affordability & price components Medicine prices matter Rapidly rising costs of health care and high medicine prices are a growing concern worldwide, especially
More informationKuwait. Medicine prices, availability, affordability and price components. Medicine prices matter
prices, availability, affordability and price components prices matter Rapidly rising costs of health care and high medicine prices are a growing concern worldwide, especially in developing and transitional
More informationMedian price ratio of salbutamol inhaler 0.1mg/dose
Median price ratio of salbutamol inhaler Median price ratio* (MPR) Countries by WHO Region Private Public Procurement Originator Generic Originator Generic Originator Generic 3.32 0.92 3.12 1.92 2.37 2.94
More informationVARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION
VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION A snapshot of data on amoxicillin, budesonide, losartan and salbutamol in eight European Union Member States Report INTRODUCTION
More informationPolicies and approaches to increase access essential medicines to treat major NCDs in both public and private facilities
Policies and approaches to increase access essential medicines to treat major NCDs in both public and private facilities Prof RohiniFernandopulleMBBS (Cey),PhD, FCGP(SL) Clinical Pharmacologists Sir John
More informationEgypt. Prices and affordability of medicines to treat noncommunicable
Egypt Prices and affordability of medicines to treat noncommunicable diseases Medicine prices matter Rapidly rising costs of health care and high medicine prices are a growing concern worldwide, especially
More informationIDA and the concept of essential drugs
International Journal of Risk & Safety in Medicine 12 (1999) 75 77 75 IOS Press IDA and the concept of essential drugs Hans V. Hogerzeil Medical Officer, WHO Department of Essential Drugs and Other Medicines,
More informationAPRIL Key Findings: Overall. Key Findings: Availability
APRIL 2006 Key Findings: Overall o Medicines were more available in private pharmacies than in other sectors o Even for medicines on the Kenya Essential Drug List, 20 out of 28 of these had below 50% availability
More informationAccess to Medicines in the Context of the Right to Health
Access to Medicines in the Context of the Right to Health An overview and WHO Perspective Human Rights Council SOCIAL FORUM 18 February 2015 Room XII, Palais des Nations, Geneva Zafar Mirza Public Health,
More informationMedicine Price. Monitor. for uganda. #12 July-September Ministry of. World Health organisation. Health Action International
Medicine Price Monitor for uganda #12 July-September 2014 Ministry of Health World Health organisation HEPS Uganda HAI AFRICA Health Action International MEDICINE PRICE MONITOR FOR UGANDA study team Survey
More informationComparative Availability of Selected Essential Medicines for Selected Common Ailments in Sonipat City
CODEN (USA)-IJPRUR, e-issn: 2348-6465 International Journal of Pharma Research and Health Sciences Available online at www.pharmahealthsciences.net Original Article Comparative Availability of Selected
More informationTobacco Health Cost in Egypt
1.Introduction 1.1 Overview Interest in the health cost of smoking originates from the desire to identify the economic burden inflicted by smoking on a society. This burden consists of medical costs plus
More informationWhat Do We Know About Access To Cardiovascular Medicine In Southern Sub Saharan Africa
What Do We Know About Access To Cardiovascular Medicine In Southern Sub Saharan Africa A. Damasceno, MD, PhD, FESC Maputo, Mozambique WORLD HEART FEDERATION AFRICAN SUMMIT KHARTOUM, SUDAN, October 2017
More informationMeasuring Access to Medicines: A Survey of Prices, Availability and Affordability in Shaanxi Province of China
Measuring Access to Medicines: A Survey of Prices, Availability and Affordability in Shaanxi Province of China Minghuan Jiang 1, Shimin Yang 1, Kangkang Yan 1, Jun Liu 1, Jun Zhao 1, Yu Fang 1,2 * 1 Department
More informationIdentifying the Barriers for Access to Care and Treatment for Arterial Hypertension and Diabetes in Lima, Peru
Identifying the Barriers for Access to Care and Treatment for Arterial Hypertension and Diabetes in Lima, Peru Executive Summary María Kathia Cárdenas, Dulce Morán, David Beran & Jaime Miranda Identifying
More informationMedicine Prices, Availability, Affordability in Kyrgyz Republic
Medicine Prices, Availability, Affordability in Kyrgyz Republic Report of a survey conducted September to October 2015 23 November, 2015 MeTA Project in Kyrgyzstan (Medicines Transparency Alliance) Bishkek
More informationWHO WIPO WTO Trilateral symposium
WHO WIPO WTO Trilateral symposium Public Health, Intellectual Property, and TRIPS at 20: Innovation and Access to Medicines : Learning from the Past, Illuminating the Future Access to Medicines: Achievements
More informationMedicine Prices,Availability and Affordability in Shaanxi Province, Western China
Medicine Prices,Availability and Affordability in Shaanxi Province, Western China Report of a survey conducted from March 26, 2012 to May 4, 2012 Yu Fang Department of Pharmacy Administration School of
More informationUnderstanding the Value of Generic Drugs
Understanding the Value of Generic Drugs Generic drugs can help you get the most out of your health care budget. 05.02.306.1 (8/05) Many people believe that when something costs more, it must be of higher
More informationThe global context for financing delivery innovations in fever case management and malaria treatment. Ramanan Laxminarayan
The global context for financing delivery innovations in fever case management and malaria treatment Ramanan Laxminarayan Changed environment 1. Greater challenges in continued funding for global health
More informationCANADIAN DIABETES ASSOCIATION
CANADIAN DIABETES ASSOCIATION Submission to the PREMIER S CONVERSATION ON HEALTH July 2007 Canadian Diabetes Association 360 1385 West 8 th Avenue Vancouver, BC V6H 3V9 Phone: (604) 732-1331 Fax: 604-732-8444
More informationAnalysis of price discrepancies and its impact on rational use of medicines
[Downloaded free from http://www.sudanmedicalmonitor.org on Tuesday, December 02, 2014, IP: 41.234.35.127] Click here to download free Android applica Original Article Analysis of price discrepancies and
More informationUP IN SMOKE: THE SOCIAL COST OF TOBACCO EXCISE
UP IN SMOKE: THE SOCIAL COST OF TOBACCO EXCISE FOREWORD BY JORDAN WILLIAMS Since the publication two years ago of our first report looking at the issue of tobacco taxes, our predictions (and warnings)
More informationAsthma Disparities: A Global Perspective
Asthma Disparities: A Global Perspective Innes Asher Department of Paediatrics: Child and Youth Health The University of Auckland, New Zealand Chair of the International Study of Asthma and Allergies in
More informationThe Danish Medicines Agency s availability strategy
låst DECEMBER 2016 The Danish Medicines Agency s availability strategy 2017 2021 Danish Medicines Agency, 2016 This publication may be freely quoted with appropriate acknowledgement of the source. Images
More informationPrescribing rationality in Khartoum state, Sudan: An update
Original Article Prescribing rationality in Khartoum state, Sudan: An update Rayan Khalid Mahmoud, Salah Ibrahim Kheder, Hassan Mohammed Ali Department of Pharmacology, Faculty of Pharmacy, National University,
More informationMedicine Price Monitor
Medicine Price Monitor Uganda No. 8 Jul-Sep 29 Medicine Price Monitor is supported by MEDICINE TRANSPARENCY ALLIANCE And published by UGANDA COUNTRY WORKING GROUP a collaboration of: MINISTRY OF HEALTH
More informationMedicine prices in Tunisia: Report of a survey. [translation of the French original] March 2004
Medicine prices in Tunisia: Report of a survey [translation of the French original] March 2004 1 ACKNOWLEDGEMENTS We would like to thank the Tunisian Ministry for Public Health [MSP] and the National Council
More informationSexual & Reproductive Health Commodities: Measuring Prices, Availability & Affordability. Findings and recommendations Uganda (2017)
Overview HEALTHY SYSTEMS, HEALTHY PEOPLE Sexual & Reproductive Health Commodities: Measuring Prices, Availability & Affordability Findings and recommendations Uganda (2017) Good sexual and reproductive
More informationRohit Malpani, Director Policy & Analysis Brussels, April 26, 2016.
Current challenges and opportunities for access to affordable medicines - a perspective from a medical humanitarian organisation Rohit Malpani, Director Policy & Analysis Brussels, April 26, 2016. Médecins
More informationPharmaceutical Sector Scan
Pharmaceutical Sector Scan Part of Component 1 of MeTA Baseline Assessments Part II - Data Forms Country: ZAMBIA Data Collected By: ANGELA TAYLOR Bsc Pharm; CHIDADZA DAKA Dip Pharm; KAMBUZA RUWE Dip Pharm;
More informationIn Australia, brand substitution of
Pharmaceutical brand substitution in Australia are there multiple switches per prescription? Abstract Background: In Australia, brand substitution by pharmacists has been possible since 1994. There is
More informationHealthy People, Healthy Communities
Healthy People, Healthy Communities Public Health Policy Statements on Public Health Issues The provincial government plays an important role in shaping policies that impact both individual and community
More informationSession 6. Evaluating the Cost of Pharmaceuticals
Drug and Therapeutics Committee Training Course Session 6. Evaluating the Cost of Pharmaceuticals Trainer s Guide Drug and Therapeutics Committee Training Course Trainer s Guide This document was made
More informationUnited Kingdom Editors:
Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen,, October 2018 LEO Innovation Lab in cooperation with The Happiness Research Institute, 2018. All rights reserved. Any part of
More informationFinancing for Family Planning: Options and Challenges
Repositioning Family Planning and Reproductive Health in the region. Financing for Family Planning: Options and Challenges BASINGA Paulin, MD,MSc, PhD Senior Lecturer School of Public Health National University
More informationPHARMACY Section 9. Overview. Preferred Drug List. Additions and Exceptions to the Preferred Drug List
Overview The management of outpatient prescription drugs is an integral part of the medical management program to improve the health and well-being of our members. Prescriber and member involvement is
More informationGeneric-brand Comparison Handbook 2010
Generic-brand Comparison Handbook 2010 The chart below provides a comparison of medications that are commonly used to treat (Information pertains to U.S. products). Generic. (Brand). Usual Dose 2012),
More informationMpho Moyo and Mariama Deen-Swarray
Gender and Entrepreneurship in the informal sector: An African perspective Mpho Moyo and Mariama Deen-Swarray CPRsouth 8/CPRafrica 2013 Mysore, India September 2013 1 Introduction limited literature on
More informationChild health and adult income. Worms at Work: Deworming and schooling in Kenya. Child health and adult income. Presentation by: Edward Miguel
Child health and adult income Do child health investments increase adult living standards? Worms at Work: Long-run Impacts of Child Health Gains Presentation by: Edward Miguel University of California,
More informationLike others here today, we are very conflicted on the FDA s proposal on behind-thecounter medications, but thank you for raising the issue.
Statement of Consumers Union William Vaughan, Senior Policy Analyst before the US Food and Drug Administration Public Meeting on Behind the Counter Availability of Drugs November 14, 2007 Consumers Union
More informationStrategies to Control Pneumonia and Diarrhoea: Tackling the deadliest diseases for the world s poorest children
Strategies to Control Pneumonia and Diarrhoea: Tackling the deadliest diseases for the world s poorest children Dr. Mark W. Young Senior Health Specialist UNICEF Programme Division New York September 24,
More informationMEDICINE PRICES SURVEY IN THE GAUTENG PROVINCE IN SOUTH AFRICA
MEDICINE PRICES SURVEY IN THE GAUTENG PROVINCE IN SOUTH AFRICA BY LIZEKA XIPHU AND NTOBEKO MPANZA NATIONAL DEPARTMENT OF HEALTH SOUTH AFRICA DECEMBER 2004 1 ACKNOWLEDGEMENTS The planning, execution and
More informationPosition Paper on Good & Services Tax (GST) on Medicines Why All Medicines Should Be Accorded GST Zero- Rate Treatment in Malaysia
Position Paper on Good & Services Tax (GST) on Medicines Why All Medicines Should Be Accorded GST Zero- Rate Treatment in Malaysia INTRODUCTION: Medicines are essential and critical goods for all Malaysian
More informationLebanon. Prices, availability, affordability and price components of medicines
Lebanon Prices, availability, affordability and price components of medicines to treat noncommunicable diseases Medicine prices matter Rapidly rising costs of health care and high medicine prices are a
More informationToolkit on monitoring health systems strengthening MEDICAL PRODUCTS, VACCINES AND TECHNOLOGIES
Toolkit on monitoring health systems strengthening MEDICAL PRODUCTS, VACCINES AND TECHNOLOGIES June 2008 Table of contents 1. Introduction... 2 2. Data sources... 2 Facility reporting systems...3 Key informant
More informationHow to evaluate the economic impact of interventions I: introduction and costing analyses
How to evaluate the economic impact of interventions I: introduction and costing analyses Raymond Hutubessy Initiative for Vaccine Research (IVR), Geneva, Switzerland Mark Jit WHO consultant, Health Protection
More informationThe Economic Burden of Hypercholesterolaemia
The Economic Burden of Hypercholesterolaemia November 2018 TABLE OF CONTENTS Acronyms 3 Executive Summary 4 Introduction 5 Approach 5 Structure of the report 5 Economic burden of hypercholesterolaemia
More informationEssential Medicines List
Essential Medicines List Mohan P. Joshi, MBBS, MSc, MD Principal Technical Advisor for Pharmaceutical Services, SIAPS West Virginia University Global Health Program Annual Summer Tropical Medicine Course
More informationSafe, effective, affordable drug choices: online tool for payers and patients.
Executive summary: Rising healthcare costs and greater access to medical information drive patients to seek options for their drug therapy. The MedAlternatives database by Gold Standard/Elsevier empowers
More informationHana Ross, PhD American Cancer Society and the International Tobacco Evidence Network (ITEN)
The Costs of Smoking Hana Ross, PhD American Cancer Society and the International Tobacco Evidence Network (ITEN) Why Do We Study the Cost of Smoking? To assess the economic impact of smoking behavior
More informationSADAG submission to the Competition Commission: Market Inquiry into the Private Healthcare Sector
THE SOUTH AFRICAN DEPRESSION AND ANXIETY GROUP NPO 013-085 Reg. No. 2000/025903/08 P O Box 652548 Benmore 2010 Tel: +27 11 234 4870 Fax: +27 11 234 8182 office@anxiety.org.za www.sadag.org SADAG submission
More informationA national survey on availability, price and affordability of selected essential medicines for non communicable diseases in Sri Lanka
Dabare et al. BMC Public Health 2014, 14:817 RESEARCH ARTICLE Open Access A national survey on availability, price and affordability of selected essential medicines for non communicable diseases in Sri
More informationStudent Projects PHARMACY PRACTICE. Keywords: Unit-of-Use, Bulk Packaging, Adherence, Economic Analysis
Unit-of-Use Versus Traditional Bulk Packaging Tiffany So¹ and Albert Wertheimer, Ph.D.¹: ¹Department of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, PA Keywords: Unit-of-Use,
More informationPharmaceutical System in the UK
Pharmaceutical System in the UK David Kullman Medicines, i Pharmacy and Industry Group Department of Health PPRI Conference, Vienna 30 September 2011 Disclaimer Conflict of interest: Nothing to disclose
More informationMedication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 update of the prevailing industry influences impacting pharmacy outcomes This page intentionally left blank Trends impacting workers compensation pharmacy
More informationAs a country in economic transition, China faces fundamental barriers to
Challenges of Health Economics and Observational Research in China Graeme Jacombs, MA, MSc (with Marco DiBonaventura, PhD) China Healthcare Reform As a country in economic transition, China faces fundamental
More informationTobacco & Poverty. Tobacco Use Makes the Poor Poorer; Tobacco Tax Increases Can Change That. Introduction. Impacts of Tobacco Use on the Poor
Policy Brief February 2018 Tobacco & Poverty Tobacco Use Makes the Poor Poorer; Tobacco Tax Increases Can Change That Introduction Tobacco use is the world s leading cause of preventable diseases and premature
More informationIllicit and illegal tobacco in North Central and North East London A report on smokers perceptions, supply and demand
Illicit and illegal tobacco in North Central and North East London A report on smokers perceptions, supply and demand Glenn Stewart, Miho Yoshizaki Public Health London Borough of Enfield November 2015
More informationPREFACE. Saskatchewan is participating in the Common Drug Review (CDR).
PREFACE OBJECTIVES The Drug Plan has been established to: provide coverage to Saskatchewan residents for quality pharmaceutical products of proven therapeutic effectiveness; reduce the direct cost of prescription
More informationDrug Use Indicators. Dr Olayinka Ogunleye Consultant Physician/Clinical Pharmacologist Department of Medicine, LASUTH, Ikeja, LAGOS
Drug Use Indicators Dr Olayinka Ogunleye Consultant Physician/Clinical Pharmacologist Department of Medicine, LASUTH, Ikeja, LAGOS 1 Background WHO (1995) Conference on Rational Use of Drugs in Nairobi
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More information1 Introduction There are health risks to people from excessive consumption of alcohol. Furthermore, excessive consumption can place a burden on society due to the cost of paying for healthcare and the
More informationThe business case for workplace HIV programmes
The business case for workplace HIV programmes Dr. Gesine Meyer-Rath Health Economics and Epidemiology Research Office (HE 2 RO) Department of Internal Medicine, Faculty of Health Sciences, University
More informationTHE HEALTH AND ECONOMIC THREATS OF NON-COMMUNICABLE DISEASES IN THE MIDDLE EAST AND NORTH AFRICA, CV BoD in Egypt/ MENA
THE HEALTH AND ECONOMIC THREATS OF NON-COMMUNICABLE DISEASES IN THE MIDDLE EAST AND NORTH AFRICA, CV BoD in Egypt/ MENA Prepared and presented by : Mahmoud Diaa Elmahdawy President, ISPOR Egypt s chapter
More informationReport. Uganda Pharmaceutical Sector Scan JUNE 2010
Report On the Uganda Pharmaceutical Sector Scan Part of Component 1 of MeTA Baseline Assessments JUNE 2010 Drafted by consultants: 1. Samuel Balyejjusa, B.Pharm., MPH 2. Paschal Mujasi, B.Pharm., MBA 3.
More informationDenmark Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen, Denmark, October 2018
Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen,, October 2018 LEO Innovation Lab in cooperation with The Happiness Research Institute, 2018. All rights reserved. Any part of
More informationEvidence based assessment of the value of innovation: pricing solutions and prospects
Evidence based assessment of the value of innovation: pricing solutions and prospects Karl Claxton 7/11/2017 How much can we pay for innovation? Cost Price > P* 60,000 30,000 per QALY Cost-effectiveness
More informationWorms at Work: Long-run Impacts of Child Health Gains
Worms at Work: Long-run Impacts of Child Health Gains Sarah Baird, George Washington University Joan Hamory Hicks, U.C. Berkeley Michael Kremer, Harvard University and NBER Edward Miguel, U.C. Berkeley
More informationGlobal Pulse Oximetry Project
3.3 Introduction of new health technologies: lessons learned Over the past twenty years there have been a number of comprehensive public health projects which illustrate important lessons regarding the
More informationSURVEY ABOUT YOUR PRESCRIPTION CHOICES
Editor s Note: This online data supplement contains supplemental material that was not included with the published article by William Shrank and colleagues, Patients' Perceptions of Generic Medications,
More informationTHE EFFECT OF COMMUNITY CHARACTERISTICS ON THE TOBACCO & ALCOHOL RETAIL ENVIRONMENT
THE EFFECT OF COMMUNITY CHARACTERISTICS ON THE TOBACCO & ALCOHOL RETAIL ENVIRONMENT Sandy Slater, MS, University of Illinois at Chicago Erin Ruel, MA, University of Illinois at Chicago Frank Chaloupka,
More informationThe Value of Providing Collaborative Care Models For Treating Employees with Depression
The Value of Providing Collaborative Care Models For Treating Employees with Depression Summary Depression is one of the costliest health issues for employers because of its high prevalence and co-morbidity
More informationKenya Perspectives. Post-2015 Development Agenda. Tuberculosis
Kenya Perspectives Post-2015 Development Agenda Tuberculosis SPEAKERS Anna Vassall Anna Vassall is Senior Lecturer in Health Economics at the London School of Hygiene and Tropical Medicine. She is a health
More informationCannabis Legalization in Alberta
Cannabis Legalization in Alberta Regulation and Supply Chain Roundtable #3 Discussion Topics Potential for cannabis cafes or lounges Public education priorities Potential for economic development Alberta
More informationTherapeutics Initiative A SHORT HISTORY
Therapeutics Initiative A SHORT HISTORY Therapeutics Initiative, 1994 (10 individuals) Mission: To provide physicians and pharmacists with up-to-date, evidence-based, practical information on prescription
More informationTOBACCO INDUSTRY MONITORING TOOL
TOBACCO INDUSTRY MONITORING TOOL CTCA MakSPH 1 Centre for Tobacco Control in Africa (CTCA) Library Cataloguing - in Publication Data Supporting African governments to build and sustain capacity for tobacco
More informationRussia Editors: LEO Innovation Lab and The Happiness R s esearch Institute Copenhagen, Denmark, October 2018
Russia Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen,, October 2018 LEO Innovation Lab in cooperation with The Happiness Research Institute, 2018. All rights reserved. Any
More informationBrazil Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen, Denmark, October 2018
Editors: LEO Innovation Lab and The Happiness Research Institute Copenhagen,, October 2018 LEO Innovation Lab in cooperation with The Happiness Research Institute, 2018. All rights reserved. Any part of
More informationPost-Trial Access Scenarios and Discussion Questions
Post-Trial Access Scenarios and Discussion Questions [Background: During the conference, we will discuss this hypothetical and its different versions. The moderator will present the scenario, and will
More informationMedicines regulation - National
Medicines regulation - National David Legge Savar, November 2018 (Several slides from Ken Harvey gratefully acknowledged) 1 National regulation Licensing of manufacturers and certification of foreign manufacture
More informationPublic Policy Agenda 2016
Public Policy Agenda 2016 1 in 26 Americans will have epilepsy over the course of their lifetime. Nearly three million children and adults in the United States have epilepsy. Epilepsy is defined as an
More informationAn Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth
An Unhealthy America: The Economic Burden of Chronic Disease Charting a New Course to Save Lives and Increase Productivity and Economic Growth Ross DeVol Director, Center for Health Economics Director,
More informationMedicine Price Monitor
Medicine Price Monitor Uganda No. 9 Apr-Jun 21 Medicine Price Monitor is supported by MEDICINE TRANSPARENCY ALLIANCE And published by UGANDA COUNTRY WORKING GROUP a collaboration of: MINISTRY OF HEALTH
More informationExtent of Medication Wastage and Cost among Female Students in a University Setting
Original Article 105 Mahidol University Journal of Pharmaceutical Science 2009; 36 (1-4), 34-43 Extent of Medication Wastage and Cost among Female Students in a University Setting S. E. Ali and M. I. M.
More informationAdvancing Access to Newer Treatments for Atrial Fibrillation. Canadian Cardiovascular Society Congress October 24, 2010 Montreal, Canada
Advancing Access to Newer Treatments for Atrial Fibrillation Canadian Cardiovascular Society Congress October 24, 2010 Montreal, Canada The Canadian Conundrum D. Wayne Taylor, PhD, F.CIM The Cameron Institute
More informationEXECUTIVE SUMMARY... 5 INTRODUCTION AND BACKGROUND:... 8 METHODOLOGY: FINDINGS: DISCUSSIONS: CONCLUSIONS ANNEXES...
TABLE OF CONTENTS Acknowledgements... 2 Acronyms... 3 Acronyms... 3 Foreword... 4 EXECUTIVE SUMMARY... 5 INTRODUCTION AND BACKGROUND:... 8 METHODOLOGY:... 12 FINDINGS:... 16 DISCUSSIONS:... 35 CONCLUSIONS...
More informationDEPARTMENT OF VETERANS AFFAIRS SUMMARY: The Department of Veterans Affairs (VA) is amending its medical
This document is scheduled to be published in the Federal Register on 03/23/2017 and available online at https://federalregister.gov/d/2017-05799, and on FDsys.gov DEPARTMENT OF VETERANS AFFAIRS 8320-01
More information61 Recommendations for better use of medications
Chapter 61 Recommendations for better use of medications As stated elsewhere in this book, we are fortunate to have a number of effective medications for treatment of many medical conditions. The drug
More information2015 Survey on Prescription Drugs
2015 Survey on Prescription Drugs AARP Research January 26, 2016 (For media inquiries, contact Gregory Phillips at 202-434-2544 or gphillips@aarp.org) https://doi.org/10.26419/res.00122.001 Objectives
More information1. This paper reports on the findings of the independent evaluation into the impact of the increases in tobacco excise duty.
In-Confidence Office of the Associate Minister of Health Chair, Cabinet Social Wellbeing Committee FINDINGS OF THE EVALUATION OF TOBACCO EXCISE INCREASES Proposal 1. This paper reports on the findings
More informationRethink. Adherence. David D. Pope, PharmD, CDE Editor-in-Chief, CreativePharmacist.com Brands
Rethink. Adherence. David D. Pope, PharmD, CDE Editor-in-Chief, CreativePharmacist.com Brands Objectives Identify patient barriers to medication adherence. Describe the clinical and economic impact of
More informationMultiple Chronic Conditions: A New Paradigm for Approaching Chronic Disease
Multiple Chronic Conditions: A New Paradigm for Approaching Chronic Disease American Medical Group Association October 26, 2012 Richard A. Goodman, MD Office of the Assistant Secretary for Health U.S.
More informationEssential Medicines for Universal Health Coverage. Highlights of the report
Essential Medicines for Universal Health Coverage Highlights of the report Scope and process Prompted by the 30 th anniversary of the 1985 Nairobi Conference on the Rational Use of Drugs, to ask: 1. What
More informationTrainers Guide. Role of Dispensers in Promoting Rational Drug Use
Trainers Guide Role of Dispensers in Promoting Rational Drug Use Materials For this session review the session notes, the overheads and the activity. If you want to do a role play of dispensing during
More informationAsia s Diabetes Challenge
Asia s Diabetes Challenge 12 th Geneva Association Health and Aging Conference Karl-Heinz Jung Head, Japan, MENA & International 1. Facts about Diabetes 2. Asia Feeling the Heat 3. Case for Private Insurance
More information